Alemtuzumab: A novel monoclonal antibody

Expert Opinion on Biological Therapy

Volumn 1, Issue 6, 2001, Pages 1059-1065

  Ferrajoli, Alessandra ^a   OBrien, Susan ^a   Keating, Michael J ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

alemtuzumab; allogeneic bone marrow transplant; chronic lymphocytic leukaemia; monoclonal antibody; prolymphocytic leukaemia; therapy

Indexed keywords

MONOCLONAL ANTIBODY;

CHRONIC LYMPHATIC LEUKEMIA; GRAFT VERSUS HOST REACTION; HUMAN; PROMYELOCYTIC LEUKEMIA; REVIEW;

ANTIBODIES, MONOCLONAL; GRAFT VS HOST DISEASE; HUMAN; LEUKEMIA, LYMPHOCYTIC, CHRONIC; LEUKEMIA, PROMYELOCYTIC, ACUTE;

EID: 0035516174     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.1.6.1059     Document Type: Article

References (50)

1. XIA MQ, HALE G, LIFELY MR et al.: Structure of the CAMPATH-1 antigen, a glycosylphosphatidylinositol-anchored glycoprotein which is an exceptionally good target for complement lysis. Biochem. J. (1993) 293:633-640.
2. HALE G, BRIGHT S, CHUMBLEY G et al.: Removal of T cells from bone marrow for transplantation: a monoclonal antilymphocyte antibody that fixes human complement. Blood (1983) 62:873-882.
3. HALE G, SWIRSKY DM, HAYHOE FG, WALDMANN H: Effects of monoclonal anti-lymphocyte antibodies in vivo in monkeys and humans. Mol. Biol. Med. (1983) 1:321-334.
4. WALDMANN H, POLLIAK A, HALE G et al.: Elimination of graft-versus-host disease by in vitro depletion of alloreactive lymphocytes with a monoclonal rat anti-human lymphocyte antibody (CAMPATH-1). Lancet (1984) 2:483-486.
5. HALE G, COBBOLD SP, WALDMANN H, EASTER G, MATEJTSCHUK P, COOMBS RR: Isolation of low-frequency class-switch variants from rat hybrid myelomas. J. Immunol. Methods (1987) 103:59-67.
6. DYER MJ, HALE G, HAYHOE FG, WALDMANN H: Effects of CAMPATH-1 antibodies in vivo in patients with lymphoid malignancies: influence of antibody isotype. Blood (1989) 73:1431-1439.
7. RIECHMANN L, CLARK M, WALDMANN H, WINTER G: Reshaping human antibodies for therapy. Nature (1988) 332:323.
8. HALE G, DYER MJ, CLARK MR et al.: Remission induction in non-Hodgkin lymphoma with reshaped human monoclonal antibody CAMPATH-1H. Lancet (1988) 2:1394-1399.
9. HALE G, WALDMANN H: The story of Campath-1. Methods Molec. Med. (2000) 40:243-266.
10. FINKELSTEIN JB: FDA panel recommends two new cancer drugs for approval. J. Natl. Cancer Inst (2001) 93:175-176.
11. HALE G: Biology of the CD52 antigen. Chronic Lymphocytic Leukemia (2001) 6:1.
12. HALE G, XIA MQ, TIGHE HP, DYER MJ, WALDMANN H: The CAMPATH-1 antigen (CDw52). Tissue Antigens (1990) 35:118-127.
13. GINALDI L, DE MARTINIS M, MATUTES E et al.: Levels of expression of CD52 in normal and leukemic B and T cells: correlation with in vivo therapeutic responses to Campath-1H. Leuk. Res. (1998) 22:185-191.
14. XIA MQ, HALE G, WALDMANN H: Efficient complement-mediated lysis of cells containing the CAMPATH-1 (CDw52) antigen. Mol. Immunol. (1993) 30:1089-1096.
15. HALE G, RYE PD, WARFORD A, LAUDER I, BRITO-BABAPULLE A: The glycosylphosphatidylinositol-anchored lymphocyte antigen CDw52 is associated with the epididymal maturation of human spermatozoa. J. Reprod. Immunol. (1993) 23:189-205.
16. ROWAN W, TITE J, TOPLEY P, BRETT SJ: Cross-linking of the CAMPATH-1 antigen (CD52) mediates growth inhibition in human B-and T-lymphoma cell lines, and subsequent emergence of CD52-deficient cells. Immunology (1998) 95:427-436.
17. HALE G, WALDMANN H: Risks of developing Epstein-Barr virus-related lymphoproliferative disorders after T-cell-depleted marrow transplants. CAMPATH Users. Blood (1998) 91:3079-3083.
18. THEOBALD M, HOFFMANN T, BUNJES D, HEIT W: Comparative analysis of in vivo T cell depletion with radiotherapy, combination chemotherapy, and the monoclonal antibody Campath-1G, using limiting dilution methodology. Transplantation (1990) 49:553-559.
19. HALE G, ZHANG MJ, BUNJES D et al.: Improving the outcome of bone marrow transplantation by using CD52 monoclonal antibodies to prevent graft-versus-host disease and graft rejection. Blood (1998) 92:4581-4590.
20. OAKHILL A, PAMPHILON DH, POTTER MN et al.: Unrelated donor bone marrow transplantation for children with relapsed acute lymphoblastic leukaemia in second complete remission. Br. J. Haematol. (1996) 94:574-578.
21. KERNAN NA, FLOMENBERG N, DUPONT B, O'REILLY RJ: Graft rejection in recipients of T-cell-depleted HLA-nonidentical marrow transplants for leukemia. Identification of host-derived antidonor allocytotoxic T lymphocytes. Trans plantation (1987) 43:842-847.
22. CHAMPLIN RE, PASSWEG JR, ZHANG MJ et al.: T-cell depletion of bone marrow transplants for leukemia from donors other than HLA-identical siblings: advantage of T-cell antibodies with narrow specificities. Blood (2000) 95:3996-4003.
23. APPERLEY JF, MAURO FR, GOLDMAN JM et al.: Bone marrow transplantation for chronic myeloid leukaemia in first chronic phase: importance of a graft-versus-leukaemia effect. Br. J. Haematol. (1988) 69:239-245.
24. NAPARSTEK E, OR R, NAGLER A et al.: T-cell-depleted allogeneic bone marrow transplantation for acute leukaemia using Campath-1 antibodies and post-transplant administration of donor's peripheral blood lymphocytes for prevention of relapse. Br. J. Haematol. (1995) 89:506-515.
25. HALE G, JACOBS P, WOOD L et al.: CD52 antibodies for prevention of graft-versus-host disease and graft rejection following transplantation of allogeneic peripheral blood stem cells. Bone Marrow T r a n s p l . (2000) 26:69-76.
26. MORGAN G, LINCH DC, KNOTT LT et al.: Successful haploidentical mismatched bone marrow transplantation in severe combined immunodeficiency: T cell removal using CAMPATH-I monoclonal antibody and E-rosetting. Br. J. Haematol. (1986) 62:421-430.
27. HAMBLIN M, MARSH JC, LAWLER M et al.: Campath-1G in vivo confers a low incidence of graft-versus-host disease associated with a high incidence of mixed chimaerism after bone marrow transplantation for severe aplastic anaemia using HLA-identical sibling donors. Bone Marrow Transpl. (1996) 17:819-824.
28. HALE G, WALDMANN H, FRIEND P, CALNE R: Pilot study of CAMPATH-1, a rat monoclonal antibody that fixes human complement, as an immunosuppressant in organ transplantation. Transplantaion (1986) 42:308-311.
29. CALNE R, MOFFATT SD, FRIEND PJ et al: Campath IH allows low-dose cyclosporine monotherapy in 31 cadaveric renal allograft recipients. Transplantation (1999) 68:1613-1616.
30. KEATING MJ. BJ, RAI K, FLINN I et al: Multicentric study of campath-1H in patients with chronic lymphocytic leukemia (B-CLL) refractory to fludarabine. Blood (1999) 94:705a.
31. OSTERBORG A, DYER MJ, BUNJES D et al: Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia. J. Clin. Oncol. (1997) 15:1567-1574.
32. KENNEDY B, ROWSTROM AC, EVANS P: Campath-1H therapy in 29 patients with refractory CLL: 'true' complete remission is an attainable goal. Blood (1999) 94:603a.
33. OSTERBORG A, FASSAS AS, ANAGNOSTOPOULOS A, DYER MJ, CATOVSKY D, MELLSTEDT H: Humanized CD52 monoclonal antibody Campath-1H as first-line treatment in chronic lymphocytic leukaemia. Br. J. Haematol (1996) 93:151-153.
34. MELLSTEDT H, OSTERBORG A, LUND IN J et al.: Campath-1H therapy of patients with previously untreated chronic lymphocytic leukemia. Blood (1998) 92:490a.
35. DYER MJ, KELSEY SM, MACKAY HJ et al: In vivo 'purging' of residual disease in CLL with Campath-1H. Br. J. Haematol (1997) 97:669-672.
36. O'BRIEN S, THOMAS D A, CORTES J et al: Campath-1H for minimal residual disease in CLL. Proceeding of the Annual Meeting of the American Society of Clinical Oncology. (2001) 20:1132a.
37. PAWSON R, DYER MJ, BARGE R et al: Treatment of T-cell prolymphocytic leukemia with human CD52 antibody. J. Clin. Oncol (1997) 15:2667-2672.
38. FERRAJOLI A, O'BRIEN S, KURZROCK R: Phase II clinical trial of Campath-1H in refractory hematological malignancies expressing the surface antigen CD-52. Proceeding of the Annual Meeting of the American Society of Clinical Oncology. (2000) 19:22a.
39. LUNDIN J, OSTERBORG A, BRITTINGER G et al: CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: a Phase II multicenter study. European Study Group of CAMPATH-1H Treatment in low-grade Non-Hodgkin's lymphoma. J. Clin. Oncol. (1998) 16:3257-3263.
40. COLES AJ, WING MG, MOLYNEUX P et al: Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis. Ann. Neurol (1999) 46:296-304.
41. COLES AJ, WING M, SMITH S et al: Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis. Lancet (1999) 354:1691-1695.
42. WATTS RA, ISAACS JD, HALE G, HAZLEMAN BL, WALDMANN H: CAMPATH-1H in inflammatory arthritis. Clin. Exp. Rheumatol. (1993) 11(Suppl. 8):S165-S167.
43. SCHNITZER TJ, YOCUM DE, MICHALSKA M et al.: Subcutaneous administration of CAMPATH-1H: clinical and biological outcomes. J. Rheumatol. (1997) 24:1031-1036.
44. LOCKWOOD CM, THIRU S, ISAACS JD, HALE G, WALDMANN H: Long-term remission of intractable systemic vasculitis with monoclonal antibody therapy. Lancet (1993) 341:1620-1622.
45. FLYNN JM, BYRD JC: Campath-1H monoclonal antibody therapy. Curr. Opin. Oncol. (2000) 12:574-581.
46. MOREAU T, COLES A, WING M et al.: Transient increase in symptoms associated with cytokine release in patients with multiple sclerosis. Brain (1996) 119:225-237.
47. FRETER C, ST. GERMAIN D, WOLFSON A: Treatment of lymphoid malignancies with Campath-1H with Campath-1H associated with elevated serum levels of IL-6 and TNF-alpha. Proceeding of the Annual Meeting of the American Society of Clinical Oncology. (1993) 12:1289a.
48. OSTERBORG A, WERNER A, HALAPI E et al.: Clonal CD8+ and CD52-T cells are induced in responding B cell lymphoma patients treated with Campath-1H (anti-CD52). Eur. J. Haematol. (1997) 58:5-13.
49. DAVISON GM, NOVITZKY N, KLINE A et al.: Immune reconstitution after allogeneic bone marrow transplantation depleted of T cells. Trans plantation (2000) 69:1341-1347.
50. WEINBLATT ME, MADDISON PJ, BULPITT KJ et al.: CAMPATH-1H, a humanized monoclonal antibody, in refractory rheumatoid arthritis. An intravenous dose-escalation study. Arthritis Rheum. (1995) 38:1589-1594.